Novartis AG (NVSN) — Capital Reinvestment Ratio
Latest as of March 2026:
0.22x
Novartis AG (NVSN) has a Capital Reinvestment Ratio of 0.22x as of March 2026, meaning it reinvests 0% of its operating cash flow (MX$3.68 Billion) in capital expenditures (MX$807.00 Million). See NVSN free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.22x
Capex / Operating Cash Flow
Operating Cash Flow
MX$3.68 Billion
MXN
Capital Expenditures
MX$807.00 Million
MXN
Data as of
Mar 2026
Most recent filing
Novartis AG Capital Reinvestment Ratio (2014–2025)
This chart tracks Novartis AG's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Novartis AG (2014–2025)
Year-by-year Capital Reinvestment Ratio for Novartis AG from 2014 to 2025. For live market cap and broader valuation context, see how much is Novartis AG worth.
| Year | Reinvestment Ratio | Operating CF (MXN) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | MX$19.14 Billion | MX$3.90 Billion | ▼ -5.9% |
| 2024 | 0.22x | MX$17.62 Billion | MX$3.81 Billion | ▲ +19.6% |
| 2023 | 0.18x | MX$16.02 Billion | MX$2.90 Billion | ▲ +115.1% |
| 2022 | 0.08x | MX$14.24 Billion | MX$1.20 Billion | ▼ -8.0% |
| 2021 | 0.09x | MX$15.07 Billion | MX$1.38 Billion | ▼ -2.1% |
| 2020 | 0.09x | MX$13.65 Billion | MX$1.27 Billion | ▼ -7.7% |
| 2019 | 0.10x | MX$13.62 Billion | MX$1.38 Billion | ▲ +15.2% |
| 2018 | 0.09x | MX$14.27 Billion | MX$1.25 Billion | ▼ -16.3% |
| 2017 | 0.10x | MX$12.62 Billion | MX$1.32 Billion | ▼ -58.2% |
| 2016 | 0.25x | MX$11.47 Billion | MX$2.88 Billion | ▲ +26.1% |
| 2015 | 0.20x | MX$11.90 Billion | MX$2.37 Billion | ▲ +5.4% |
| 2014 | 0.19x | MX$13.90 Billion | MX$2.62 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow